Verrica Q3 revenue $14.3M (YCANTH $3.6M, license $10.7M); net loss narrows to $0.3M

Verrica Pharmaceuticals Inc.

2025-Q3 EPS reported -$1.03 vs consensus -$0.69 ▼ miss (-49.6%)

Q3 net loss $0.3M ($0.03/sh) vs $22.9M loss ($4.88/sh) in Q3'24; non-GAAP net income $1.2M.
YCANTH dispensed units 14,093 in Q3 (+4.9% sequentially); nine-month total 37,642 (+120% YoY).
Received $10M milestone from Torii for Japan YCANTH approval; global Phase 3 for common warts started.
FDA aligned on Phase 3 design for VP-315 in basal cell carcinoma; positive EMA feedback supports MAA filing.
Cash $21.1M; sales force expanded to 45 reps, targeting 50 in 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.